Warning letter
Cayman Chemical Company [ARCHIVED]: warning letter of Jan 19, 2010
FDA warning letter 88544 · Center for Drug Evaluation and Research
Key facts
| Reference number | 88544 |
|---|---|
| Company | Cayman Chemical Company [ARCHIVED] |
| Subject | Sponsor/Monitor/Contract Research Organization |
| Issue date | Jan 19, 2010 |
| Posted date | Jan 19, 2010 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 50.23, 56, 50, 50.20, 50.27(a), 312, 312.40, 312.66, 312.60, 312.8(a)(3), 312.57(a), 312.3(b) and 3 more |
| Inspection city | Ann Arbor |
| Inspection ZIP | 48108 |
| Inspection start date | May 12, 2009 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: